07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)

Cancer INDICATION: Breast cancer Patient sample and cell studies suggest inhibiting EIF4B or MCL1 could help treat basal breast cancer. In tumor samples from breast cancer patients, MCL1 levels were higher in the aggressive basal...
07:00 , Jun 22, 2009 |  BioCentury  |  Product Development

Targeting Akt & MEK

Targeting Akt & MEK By targeting both Akt and MEK , AstraZeneca plc (LSE:AZN; NYSE:AZN) and Merck & Co. Inc. (NYSE:MRK) hope to create a cancer therapy that blocks two separate signaling pathways involved in...
07:00 , Jun 22, 2009 |  BioCentury  |  Product Development

Now the Tricky Part

Now that AstraZeneca plc and Merck & Co. Inc. have concluded there is a strong mechanistic case for combining their respective MEK and Akt inhibitors for a Phase I trial, the partners must figure out...